Clinical Trial Update: A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of SHB-04-CD22 CAR-T therapy targeting CD22 in CD22-expressing B-cell malignancies; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• SHB-04-CD22

Snippet

Sponsor: Sheba Medical Center | Conditions: B Cell Malignancies | Phase 1, Phase 2 | Status: RECRUITING